2021 AMI Online Salon
Treatment Targets of Disease-Modifying Therapies Currently Approved for Multiple Sclerosis
Project Details
- Entrant Name: Lohitha Kethu
- Client: Journal of the American Medical Association
- Copyright: American Medical Association, 2021
- Medium/software used: Adobe Photohop, Illustrator
- Final presentation format: Journal article online and in print
- Primary Audience: General clinicians and researchers
Project Description
Multiple sclerosis (MS) is an autoimmune central nervous system disorder characterized by neuroinflammation, demyelination, and axonal transection (severed axons), that have been linked to irreversible neurologic degeneration and can affect physical function, cognition, and quality of life. Although the pathophysiology of MS is not fully understood, significant disease modifying therapies (DMTs) are available that target cellular and molecular pathways which are currently known. DMTs decelerate neurological damage and reduce the chance of relapse; Most available DMTs work by diminishing neuroinflammation at or before the level of the blood-brain-barrier in order to slow disease progression. This figure provides a dynamic overview of the types of drugs, mechanisms of action, and roles in the known pathophysiological context of MS.
